Clinicians managing patients with behavioral health issues are presented with various diagnostic and treatment challenges, spanning the areas of neurobiology, adherence, safety, and medication tolerability. Currently available pharmacotherapeutic, psychotherapeutic, and combination therapies often provide inadequate or only partial responses, leaving patients with a host of residual symptoms. Neuromodulation techniques, including transcranial magnetic stimulation (TMS), deep brain stimulation (DBS) and others, have been gaining favor among experts as alternative options for addressing those experiencing inadequate response with more traditional treatment regimens.

In this Virtual Forum, join Philip G. Janicak, MD, and Michael Thase, MD, as they discuss the state of the science in neuromodulation techniques. Speakers will discuss their perspectives and the supporting evidence for various forms of neuromodulation in the treatment of mental health disorders, with a focus on depression. Speakers are paid consultants for Otsuka Pharmaceutical Development & Commercialization, Inc.

**Philip G. Janicak, MD**
Adjunct Professor, Department of Psychiatry & Behavioral Sciences, Northwestern University, Feinberg School of Medicine; Director, Transcranial Magnetic Stimulation Center, Edward/Elmhurst Healthcare; & Consultant, Neuromodulation Center, Northwestern University.

**Michael Thase, MD**
Professor, Psychiatry, & Director, Mood & Anxiety Disorders Treatment & Research Program, University of Pennsylvania Perelman School of Medicine; & Member, medical staff, Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania.

**Mark Tacelosky, PharmD,** Medical Science Liaison for Otsuka Pharmaceutical Development & Commercialization, Inc., will be the moderator of this event.